Bladder cancer immunotherapy: BCG and beyond

Advances in Urology

Volumn , Issue , 2012, Pages

  Askeland, Eric J ^a   Newton, Mark R ^a   O'Donnell, Michael A ^a   Luo, Yi ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863691349     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/181987     Document Type: Review

References (160)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012 CA Cancer Journal for Clinicians 2012 62 1 10 29
2. Ro J. Y., Staerkel G. A., Ayala A. G., Cytologic and histologic features of superficial bladder cancer Urologic Clinics of North America 1992 19 3 435 453
3. Kemp T. J., Ludwig A. T., Earel J. K., Moore J. M., VanOosten R. L., Moses B., Leidal K., Nauseef W. M., Griffith T. S., Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood 2005 106 10 3474 3482 (Pubitemid 41609183)
4. Morales A., Eidinger D., Bruce A. W., Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors Journal of Urology 1976 116 2 180 183
5. Hall M. C., Chang S. S., Dalbagni G., Pruthi R. S., Seigne J. D., Skinner E. C., Wolf J. S., Schellhammer P. F., Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update Journal of Urology 2007 178 6 2314 2330 (Pubitemid 350080987)
6. Lamm D. L., Blumenstein B. A., Crawford E. D., Montie J. E., Scardino P., Grossman H. B., Stanisic T. H., Smith J. A., Sullivan J., Sarosdy M. F., Crissman J. D., Coltman C. A., A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder New England Journal of Medicine 1991 325 17 1205 1209
7. Morales A., Ottenhof P., Emerson L., Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin Journal of Urology 1981 125 5 649 651 (Pubitemid 11123149)
8. Malmstrm P. U., Wijkstrm H., Lundholm C., Wester K., Busch C., Norlén B. J., Ekman P., Karlberg L., Ohlsson J. O., Lindeborg T., Malmstrm P. U., Norming U., Wijkstrm H., Susskind S., Sten J., Lagerkvist M., Jansson S., Tveter K. J., 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma Journal of Urology 1999 161 4 1124 1127 (Pubitemid 29426100)
9. Van der Meijden A. P. M., Sylvester R. J., Oosterlinck W., Hoeltl W., Bono A. V., Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III trial European Urology 2003 44 4 429 434 (Pubitemid 37185667)
10. Kavoussi L. R., Brown E. J., Ritchey J. K., Ratliff T. L., Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response Journal of Clinical Investigation 1990 85 1 62 67 (Pubitemid 20030291)
11. Zuiverloon T. C. M., Nieuweboer A. J. M., Vékony H., Kirkels W. J., Bangma C. H., Zwarthoff E. C., Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review European Urology 2012 61 1 128 145
12. Luo Y., Chen X., O'Donnell M. A., Role of Th1 and Th2 cytokines in BCG-induced IFN- production: cytokine promotion and simulation of BCG effect Cytokine 2003 21 1 17 26 (Pubitemid 36369372)
13. Kaempfer R., Gerez L., Farbstein H., Madar L., Hirschman O., Nussinovich R., Shapiro A., Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression Journal of Clinical Oncology 1996 14 6 1778 1786 (Pubitemid 26185455)
14. Thalmann G. N., Sermier A., Rentsch C., Mhrle K., Cecchini M. G., Studer U. E., Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin Journal of Urology 2000 164 6 2129 2133
15. Saint F., Patard J. J., Maille P., Soyeux P., Hoznek A., Salomon L., Abbou C. C., Chopin D. K., Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer Journal of Urology 2002 167 1 364 367 (Pubitemid 34024586)
16. De Reijke T. M., De Boer E. C., Kurth K. H., Schamhart D. H. J., Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value Journal of Urology 1996 155 2 477 482 (Pubitemid 26023528)
17. Lamm D. L., Blumenstein B. A., Crissman J. D., Montie J. E., Gottesman J. E., Lowe B. A., Sarosdy M. F., Bohl R. D., Grossman H. B., Beck T. M., Leimert J. T., Crawford E. D., Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study Journal of Urology 2000 163 4 1124 1129 (Pubitemid 30169376)
18. Jonasch E., Haluska F. G., Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities Oncologist 2001 6 1 34 55 (Pubitemid 32155814)
19. Kamat A. M., Lamm D. L., Immunotherapy for bladder cancer Current urology Reports 2001 2 1 62 69
20. Belardelli F., Ferrantini M., Proietti E., Kirkwood J. M., Interferon-alpha in tumor immunity and immunotherapy Cytokine and Growth Factor Reviews 2002 13 2 119 134 (Pubitemid 34229387)
21. Papageorgiou A., Lashinger L., Millikan R., Grossman H. B., Benedict W., Dinney C. P. N., McConkey D. J., Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells Cancer Research 2004 64 24 8973 8979 (Pubitemid 39665506)
22. Tecchio C., Huber V., Scapini P., Calzetti F., Margotto D., Todeschini G., Pilla L., Martinelli G., Pizzolo G., Rivoltini L., Cassatella M. A., IFN -stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells Blood 2004 103 10 3837 3844 (Pubitemid 38596303)
23. Papageorgiou A., Dinney C. P. N., McConkey D. J., Interferon- induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells Cancer Biology and Therapy 2007 6 6 872 879 (Pubitemid 351574976)
24. Ludwig A. T., Moore J. M., Luo Y., Chen X., Saltsgaver N. A., O'Donnell M. A., Griffith T. S., Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity Cancer Research 2004 64 10 3386 3390 (Pubitemid 38657909)
25. Droller M. J., Gomolka D., Enhancement of natural cytotoxicity in lymphocytes from animals with carcinogen-induced bladder cancer Journal of Urology 1983 129 3 625 629 (Pubitemid 13128804)
26. Parronchi P., De Carli M., Manetti R., Simonelli C., Sampognaro S., Piccinni M. P., Macchia D., Maggi E., Del Prete G., Romagnani S., IL-4 and IFN ( and ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones Journal of Immunology 1992 149 9 2977 2983
27. Slaton J. W., Perrotte P., Inoue K., Dinney C. P. N., Fidler I. J., Interferon- -mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule Clinical Cancer Research 1999 5 10 2726 2734 (Pubitemid 29493945)
28. Giannopoulos A., Adamakis I., Evangelou K., Giannopoulou M., Zacharatos P., Tsantoulis P., Perunovic B., Athanasiou A., Retalis G., Constandinidis C., Gorgoulis V. G., Interferon-a2b reduces neo-microvascular density in the 'normal' urothelium adjacent to the tumor after transurethral resection of superficial bladder carcinoma Onkologie 2003 26 2 147 152 (Pubitemid 36677079)
29. Glashan R. W., A randomized controlled study of intravesical -2b-interferon in carcinoma in situ of the bladder Journal of Urology 1990 144 3 658 661 (Pubitemid 20296718)
30. Hudson M. A., Ratliff T. L., Failure of intravesical interferon-alfa-2b for the treatment of patients with superficial bladder cancer previously failing intravesical BCG Therapy Urologic Oncology 1995 1 3 115 118
31. Portillo J., Martin B., Hernandez R., Correas M., Gutierrez J., Del Valle J., Roca A., Vega A., Villanueva A., Gutierrez R., Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder Urology 1997 49 2 187 190
32. Gan Y. H., Zhang Y., Khoo H. E., Esuvaranathan K., Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer European Journal of Cancer 1999 35 7 1123 1129 (Pubitemid 29339197)
33. Luo Y., Chen X., Downs T. M., DeWolf W. C., O'Donnell M. A., IFN- 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy Journal of Immunology 1999 162 4 2399 2405 (Pubitemid 29288868)
34. Stricker P., Pryor K., Nicholson T., Goldstein D., Golovsky D., Ferguson R., Nash P., Ehsman S., Rumma J., Mammen G., Penny R., Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer Urology 1996 48 6 957 962
35. O'Donnell M. A., Krohn J., DeWolf W. C., Salvage intravesical therapy with interferon- 2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed Journal of Urology 2001 166 4 1300 1304 (Pubitemid 32862161)
36. Lam J. S., Benson M. C., O'Donnell M. A., Sawczuk A., Gavazzi A., Wechsler M. H., Sawczuk I. S., Bacillus Calmete-Guérin plus interferon- 2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity Urologic Oncology 2003 21 5 354 360 (Pubitemid 38534176)
37. Punnen S. P., Chin J. L., Jewett M. A., Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy The Canadian Journal of Urology 2003 10 2 1790 1795
38. Joudi F. N., Smith B. J., O'Donnell M. A., Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon -2B for reducing recurrence of superficial bladder cancer Urologic Oncology 2006 24 4 344 348 (Pubitemid 43963411)
39. Bazarbashi S., Soudy H., Abdelsalam M., Al-Jubran A., Akhtar S., Memon M., Aslam M., Kattan S., Shoukri M., Co-administration of intravesical bacillus Calmette-Guérin and interferon -2B as first line in treating superficial transitional cell carcinoma of the urinary bladder British Journal of Urology International 2011 108 7 1115 1118
40. Gallagher B. L., Joudi F. N., Maym J. L., O'Donnell M. A., Impact of previous Bacille Calmette-Guérin failure pattern on subsequent response to Bacille Calmette-Guérin plus interferon intravesical therapy Urology 2008 71 2 297 301 (Pubitemid 351282357)
41. Nepple K. G., Lightfoot A. J., Rosevear H. M., O'Donnell M. A., Lamm D. L., Bacillus Calmette-Guréin with or without interferon -2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer Journal of Urology 2010 184 5 1915 1919
42. Luo Y., Chen X., Han R., O'Donnell M. A., Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity Clinical and Experimental Immunology 2001 123 2 264 270 (Pubitemid 32174778)
43. Liu W., O'Donnell M. A., Chen X., Han R., Luo Y., Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro Cancer Immunology, Immunotherapy 2009 58 10 1647 1655
44. Louie B., Rajamahanty S., Won J., Choudhury M., Konno S., Synergistic potentiation of interferon activity with maitake mushroom d-fraction on bladder cancer cells British Journal of Urology International 2010 105 7 1011 1015
45. Fishman A.I., Johnson B., Alexander B., Won J., Choudhury M., Konno S., Additively enhanced antiproliferative effect of interferon combined with proanthocyanidin on bladder cancer cells Journal of Cancer 2012 3 107 112
46. Nagabhushan T. L., Maneval D. C., Benedict W. F., Wen S. F., Ihnat P. M., Engler H., Connor R. J., Enhancement of intravesical delivery with Syn3 potentiates interferon- 2b gene therapy for superficial bladder cancer Cytokine and Growth Factor Reviews 2007 18 5-6 389 394 (Pubitemid 47302827)
47. Gillis S., Smith K. A., Long term culture of tumour specific cytotoxic T cells Nature 1977 268 5616 154 156 (Pubitemid 8125246)
48. Di Sabato G., Chen D. M., Erickson J. W., Production by murine spleen cells of an activity stimulating the PHA responsiveness of thymus lymphocytes Cellular Immunology 1975 17 2 495 504
49. Chen D. M., Di Sabato G., Further studies on the thymocyte stimulating factor Cellular Immunology 1976 22 2 211 224
50. Mizel S. B., Farrar J. J., Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors Cellular Immunology 1979 48 2 433 436
51. Shaw J., Monticone V., Mills G., Paetkau V., Effects of costimulator on immune responses in vitro Journal of Immunology 1978 120 6 1974 1980 (Pubitemid 8356943)
52. Yron I., Wood T. A., Spiess P. J., Rosenberg S. A., In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors Journal of Immunology 1980 125 1 238 245 (Pubitemid 10040428)
53. Lotze M. T., Grimm E. A., Mazumder A., Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor Cancer Research 1981 41 11 I 4420 4425 (Pubitemid 12201351)
54. Henney C. S., Kuribayashi K., Kern D. E., Gillis S., Interleukin-2 augments natural killer cell activity Nature 1981 291 5813 335 338 (Pubitemid 11083437)
55. Malkovsky M., Loveland B., North M., Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes Nature 1987 325 6101 262 265 (Pubitemid 17049887)
56. Waldmann T. A., Goldman C. K., Robb R. J., Expression of interleukin 2 receptors on activated human B cells Journal of Experimental Medicine 1984 160 5 1450 1466 (Pubitemid 15220774)
57. Mosmann T. R., Cherwinski H., Bond M. W., Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins Journal of Immunology 1986 136 7 2348 2357 (Pubitemid 16136806)
58. Rosenberg S. A., Lotze M. T., Muul L. M., A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone New England Journal of Medicine 1987 316 15 889 897 (Pubitemid 17041979)
59. Webb D. E., Austin H. A., Belldegrun A., Vaughan E., Linehan W. M., Rosenberg S. A., Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer Clinical Nephrology 1988 30 3 141 145
60. Ratliff T. L., Haaff E. O., Catalona W. J., Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer Clinical Immunology and Immunopathology 1986 40 2 375 379 (Pubitemid 16066115)
61. Haaff E. O., Catalona W. J., Ratliff T. L., Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG Journal of Urology 1986 136 4 970 974 (Pubitemid 16026263)
62. De Jong W. H., De Boer E. C., Van Der Meijden A. P. M., Vegt P., Steerenberg P. A., Debruyne F. M. J., Ruitenberg E. J., Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guerin Cancer Immunology Immunotherapy 1990 31 3 182 186 (Pubitemid 20150148)
63. Bhle A., Nowe C., Ulmer A. J., Musehold J., Gerdes J., Hofstetter A. G., Flad H. D., Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma Cytokine 1990 2 3 175 181
64. De Boer E. C., De Jong W. H., Steerenberg P. A., Van Der Meijden A. P. M., Aarden L. A., Debruyne F. M. J., Ruitenberg E. J., Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with Bacillus Calmette-Guerine In Vivo 1991 5 6 671 678
65. De Boer E. C., De Jong W. H., Steerenberg P. A., Aarden L. A., Tetteroo E., De Groot E. R., Van der Meijden A. P. M., Vegt P. D. J., Debruyne F. M. J., Ruitenberg E. J., Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer Cancer Immunology Immunotherapy 1992 34 5 306 312
66. Balbay D., Bakkaloglu M., zen H., Tasar C., zkardes H., Remzi D., Barut A., Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy Urology 1994 43 2 187 190 (Pubitemid 24065870)
67. De Reijke T. M., De Boer E. C., Kurth K. H., Schamhart D. H. J., Urinary interleukin-2 monitoring during prolonged bacillus Calmette- Guerin treatment: can it predict the optimal number of instillations? Journal of Urology 1999 161 1 67 71 (Pubitemid 29422293)
68. Taniguchi K., Koga S., Nishikido M., Yamashita S., Sakuragi T., Kanetake H., Saito Y., Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer Clinical and Experimental Immunology 1999 115 1 131 135 (Pubitemid 29030375)
69. Magno C., Melloni D., Gal A., Mucciardi G., Nicocia G., Morandi B., Melioli G., Ferlazzo G., The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2 Immunology Letters 2002 81 3 235 238 (Pubitemid 34310231)
70. Pizza G., Severini G., Menniti D., Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report International Journal of Cancer 1984 34 3 359 367 (Pubitemid 14032186)
71. Lee K. E., Weiss G. H., O'Donnell R. W., Cockett A. T. K., Reduction of bladder cancer growth in mice treated with intravesical Bacillus Calmette Guerin and systemic Interleukin 2 Journal of Urology 1987 137 6 1270 1273 (Pubitemid 17079081)
72. Ikemoto S., Kamizuru M., Wada S., Nishio S., Kishimoto T., Maekawa M., Combined effect of interleukin 2 and Bacillus Calmette-Guerin in the therapy of mice with transitional cell carcinoma Urologia Internationalis 1991 47 4 250 254
73. Riggs D. R., Tarry W. F., DeHaven J. I., Sosnowski J., Lamm D. L., Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy Journal of Urology 1992 147 1 212 214
74. Tubaro A., Velotti F., Stoppacciaro A., Santoni A., Vicentini C., Bossola P. C., Galassi P., Pettinato A., Morrone S., Napolitano T., Frati L., Ruco L., Franks C. R., Palmer P. A., Pourreau C. N., Miano L., Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer: a phase IB study Cancer 1991 68 1 56 61
75. Merguerian P. A., Donahue L., Cockett A. T. K., Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report Journal of Urology 1987 137 2 216 219 (Pubitemid 17016633)
76. Huland E., Huland H., Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma Cancer Research 1989 49 19 5469 5474 (Pubitemid 19240491)
77. Cockett A. T. K., Davis R. S., Cos L. R., Wheeless L. L., Bacillus calmette-guerin and interleukin-2 for treatment of superficial bladder cancer Journal of Urology 1991 146 3 766 770
78. Gomella L. G., McGinnis D. E., Lattime E. C., Butler K., Baltish M., Thompson I., Marshall M. E., Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study Cancer Biotherapy 1993 8 3 223 227 (Pubitemid 23321989)
79. Den Otter W., Dobrowolski Z., Bugajski A., Papla B., Van Der Meijden A. P. M., Koten J. W., Boon T. A., Siedlar M., Zembala M., Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients Journal of Urology 1998 159 4 1183 1186 (Pubitemid 28172790)
80. O'Donnell M. A., Aldovini A., Duda R. B., Yang H., Szilvasi A., Young R. A., DeWolf W. C., Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes Infection and Immunity 1994 62 6 2508 2514 (Pubitemid 24157083)
81. Murray P. J., Aldovini A., Young R. A., Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines Proceedings of the National Academy of Sciences of the United States of America 1996 93 2 934 939
82. Slobbe L., Lockhart E., O'Donnell M. A., Mackintosh C., De Lisle G., Buchan G., An in vivo comparison of bacillus Calmette-Guerin (BCG) and cytokine- secreting BCG vaccines Immunology 1999 96 4 517 523 (Pubitemid 29179788)
83. Yamada H., Matsumoto S., Matsumoto T., Yamada T., Yamashita U., Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2 Journal of Urology 2000 164 2 526 531 (Pubitemid 30481978)
84. Luo Y., Chen X., Szilvasi A., O'Donnell M. A., Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity Molecular Immunology 2000 37 9 527 536 (Pubitemid 32001694)
85. Young S. L., O'Donnell M. A., Buchan G. S., IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosupression to elicit a Type 1 immune response International Immunology 2002 14 7 793 800 (Pubitemid 34814640)
86. Li Y. G., Wang Z. P., Tian J. Q., Tian B. Q., Rodrigues R., Shang P. F., Zhang T., Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of t-lymphocyte in human bladder tumor cell s in vitro Cancer Investigation 2009 27 9 909 917
87. Huang X., Yu H. S., Chen Z., Li J. L., Hu Z. M., Gao J. M., A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall Chinese Journal of Cancer 2010 29 6 611 616
88. Zhang X., Shi X., Li J., Hu Z., Guo F., Huang X., Zhang Z., Sun P., Jing Y., Gao J., Tan W., Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells Urology 2011 78 3 722.el 722.e6
89. Wong H. L., Wilson D. E., Jenson J. C., Familletti P. C., Stremlo D. L., Gately M. K., Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro Cellular Immunology 1988 111 1 39 54 (Pubitemid 18057047)
90. Kobayashi M., Fitz L., Ryan M., Hewick R. M., Clark S. C., Chan S., Loudon R., Sherman F., Perussia B., Trinchieri G., Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes Journal of Experimental Medicine 1989 170 3 827 845 (Pubitemid 19226667)
91. Stern A. S., Podlaski F. J., Hulmes J. D., Pan Y. C. E., Quinn P. M., Wolitzky A. G., Familletti P. C., Stremlo D. L., Truitt T., Chizzonite R., Gately M. K., Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells Proceedings of the National Academy of Sciences of the United States of America 1990 87 17 6808 6812
92. Gately M. K., Desai B. B., Wolitzky A. G., Quinn P. M., Dwyer C. M., Podlaski F. J., Familletti P. C., Sinigaglia F., Chizonnite R., Gubler U., Stern A. S., Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor) Journal of Immunology 1991 147 3 874 882
93. Gubler U., Chua A. O., Schoenhaut D. S., Dwyer C. M., McComas W., Motyka R., Nabavi N., Wolitzky A. G., Quinn P. M., Familletti P. C., Gately M. K., Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor Proceedings of the National Academy of Sciences of the United States of America 1991 88 10 4143 4147 (Pubitemid 21914495)
94. Schoenhaut D. S., Chua A. O., Wolitzky A. G., Quinn P. M., Dwyer C. M., McComas W., Familletti P. C., Gately M. K., Gubler U., Cloning and expression of murine IL-12 Journal of Immunology 1992 148 11 3433 3440
95. Desai B. B., Quinn P. M., Wolitzky A. G., Mongini P. K. A., Chizzonite R., Gately M. K., IL-12 receptor. II. Distribution and regulation of receptor expression Journal of Immunology 1992 148 10 3125 3132
96. Manetti R., Parronchi P., Giudizi M. G., Piccinni M. P., Maggi E., Trinchieri G., Romagnani S., Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells Journal of Experimental Medicine 1993 177 4 1199 1204 (Pubitemid 23097410)
97. Macatonia S. E., Hosken N. A., Litton M., Vieira P., Hsieh C. S., Culpepper J. A., Wysocka M., Trinchieri G., Murphy K. M., O'Garra A., Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells Journal of Immunology 1995 154 10 5071 5079
98. Gately M. K., Wolitzky A. G., Quinn P. M., Chizzonite R., Regulation of human cytolytic lymphocyte responses by interleukin-12 Cellular Immunology 1992 143 1 127 142
99. Collison K., Saleh S., Parhar R., Meyer B., Kwaasi A., Ai-Hussein K., Al-Sedairy S., Al-Mohanna F., Evidence for IL-12-activated Ca 2+ and tyrosine signaling pathways in human neutrophils Journal of Immunology 1998 161 7 3737 3745
100. Yeaman G. R., Collins J. E., Currie J. K., Guyre P. M., Wira C. R., Fanger M. W., IFN- is produced by polymorphonuclear neutrophils in human uterine endometrium and by cultured peripheral blood polymorphonuclear neutrophils Journal of Immunology 1998 160 10 5145 5153 (Pubitemid 28215354)
101. Voest E. E., Kenyon B. M., O'Reilly M. S., Truitt G., D'Amato R. J., Folkman J., Inhibition of angiogenesis in vivo by interleukin 12 Journal of the National Cancer Institute 1995 87 8 581 586
102. Dias S., Boyd R., Balkwill F., IL-12 regulates VEGF and MMPs in a murine breast cancer model International Journal of Cancer 1998 78 3 361 365 (Pubitemid 28445375)
103. Coughlin C. M., Salhany K. E., Gee M. S., LaTemple D. C., Kotenko S., Ma X., Gri G., Wysocka M., Kim J. E., Liu L., Liao F., Farber J. M., Pestka S., Trinchieri G., Lee W. M. F., Tumor cell responses to IFN affect tumorigenicity and response to IL- 12 therapy and antiangiogenesis Immunity 1998 9 1 25 34 (Pubitemid 28361292)
104. Coughlin C. M., Salhany K. E., Wysocka M., Aruga E., Kurzawa H., Chang A. E., Hunter C. A., Fox J. C., Trinchieri G., Lee W. M. F., Interleukin-12, and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis Journal of Clinical Investigation 1998 101 6 1441 1452 (Pubitemid 28145262)
105. Hashimoto W., Osaki T., Okamura H., Robbins P. D., Kurimoto M., Nagata S., Lotze M. T., Tahara H., Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin- induced tumor apoptosis, respectively Journal of Immunology 1999 163 2 583 589 (Pubitemid 29328059)
106. Kawamura T., Takeda K., Mendiratta S. K., Kawamura H., Van Kaer L., Yagita H., Abo T., Okumura K., Cutting edge: critical role of NK1 T cells in IL-12-induced immune responses in vivo Journal of Immunology 1998 160 1 16 19 (Pubitemid 28116708)
107. Brunda M. J., Luistro L., Warrier R. R., Wright R. B., Hubbard B. R., Murphy M., Wolf S. F., Gately M. K., Antitumor and antimetastatic activity of interleukin 12 against murine tumors Journal of Experimental Medicine 1993 178 4 1223 1230 (Pubitemid 23277355)
108. Nastala C. L., Edington H. D., McKinney T. G., Tahara H., Nalesnik M. A., Brunda M. J., Gately M. K., Wolf S. F., Schreiber R. D., Storkus W. J., Lotze M. T., Recombinant IL-12 administration induces tumor regression in association with IFN- production Journal of Immunology 1994 153 4 1697 1706 (Pubitemid 24251114)
109. Teicher B. A., Ara G., Buxton D., Leonard J., Schaub R. G., Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma Clinical Cancer Research 1997 3 9 1661 1667 (Pubitemid 27431577)
110. Teicher B. A., Ara G., Buxton D., Leonard J., Schaub R. G., Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine lewis lung carcinoma Radiation Oncology Investigations 1998 6 2 71 80 (Pubitemid 28185738)
111. O'Donnell M. A., Luo Y., Hunter S. E., Chen X., Hayes L. L., Clinton S. K., Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity Journal of Urology 2004 171 3 1330 1335 (Pubitemid 38327605)
112. Zagozdzon R. S., Giermasz A., Golab J., Stoklosa T., Jalili A., Jakbisiak M., The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production Cancer Letters 1999 147 1-2 67 75
113. Zagozdzon R., Golab J., Mucha K., Foroncewicz B., Jakobisiak M., Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo International Journal of Molecular Medicine 1999 4 6 645 648
114. Golab J., Zagozdzon R., Kozar K., Kaminski R., Giermasz A., Stoklosa T., Lasek W., Jakbisiak M., Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo Oncology Reports 2000 7 1 177 181
115. Teicher B. A., Ara G., Menon K., Schaub R. G., In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment International Journal of Cancer 1996 65 1 80 84 (Pubitemid 26027540)
116. Lieu F. H. L., Hawley T. S., Fong A. Z. C., Hawley R. G., Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: implications for immune gene therapy Cancer Gene Therapy 1997 4 3 167 175 (Pubitemid 127667112)
117. Bramson J. L., Hitt M., Addison C. L., Muller W. J., Gauldie J., Graham F. L., Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 Human Gene Therapy 1996 7 16 1995 2002 (Pubitemid 26390239)
118. Addison C. L., Bramson J. L., Hitt M. M., Muller W. J., Gauldie J., Graham F. L., Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors Gene Therapy 1998 5 10 1400 1409 (Pubitemid 28482668)
119. Meko J. B., Yim J. H., Tsung K., Norton J. A., High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12 Cancer Research 1995 55 21 4765 4770
120. Zitvogel L., Tahara H., Cai Q., Storkus W. J., Muller G., Wolf S. F., Gately M., Robbins P. D., Lotze M. T., Construction and characterization of retroviral vectors expressing biologically active human interleukin-12 Human Gene Therapy 1994 5 12 1493 1506
121. O'Donnell M. A., Luo Y., Chen X., Szilvasi A., Hunter S. E., Clinton S. K., Role of IL-12 in the induction and potentiation of IFN- in response to bacillus Calmette-Guerin Journal of Immunology 1999 163 8 4246 4252 (Pubitemid 29474489)
122. Riemensberger J., Bhle A., Brandau S., IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer Clinical and Experimental Immunology 2002 127 1 20 26 (Pubitemid 34155453)
123. O'Donnell M. A., Luo Y., Hunter S. E., Chen X., Hayes L. L., Clinton S. K., The essential role of interferon- during interleukin-12 therapy for murine transitional cell carcinoma of the bladder Journal of Urology 2004 171 3 1336 1342 (Pubitemid 38327606)
124. Horinaga M., Harsch K. M., Fukuyama R., Heston W., Larchian W., Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model Urology 2005 66 2 461 466 (Pubitemid 41138125)
125. Zaharoff D. A., Hoffman B. S., Hooper H. B., Benjamin C. J., Khurana K. K., Hance K. W., Rogers C. J., Pinto P. A., Schlom J., Greiner J. W., Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12 Cancer Research 2009 69 15 6192 6199
126. Cohen J., IL-12 deaths: explanation and a puzzle Science 1995 270 5238 908
127. Atkins M. B., Robertson M. J., Gordon M., Lotze M. T., DeCoste M., DuBois J. S., Ritz J., Sandler A. B., Edington H. D., Garzone P. D., Mier J. W., Canning C. M., Battiato L., Tahara H., Sherman M. L., Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies Clinical Cancer Research 1997 3 3 409 417 (Pubitemid 27158065)
128. Robertson M. J., Cameron C., Atkins M. B., Gordon M. S., Lotze M. T., Sherman M. L., Ritz J., Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer Clinical Cancer Research 1999 5 1 9 16 (Pubitemid 29045172)
129. Gollob J. A., Mier J. W., Veenstra K., McDermott D. F., Clancy D., Clancy M., Atkins M. B., Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN- induction is associated with clinical response Clinical Cancer Research 2000 6 5 1678 1692 (Pubitemid 30305060)
130. Hurteau J. A., Blessing J. A., DeCesare S. L., Creasman W. T., Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study Gynecologic Oncology 2001 82 1 7 10 (Pubitemid 32634946)
131. Motzer R. J., Rakhit A., Thompson J. A., Nemunaitis J., Murphy B. A., Ellerhorst J., Schwartz L. H., Berg W. J., Bukowski R. M., Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon- 2a for patients with advanced renal cell carcinoma Journal of Interferon and Cytokine Research 2001 21 4 257 263 (Pubitemid 32680910)
132. Lenzi R., Rosenblum M., Verschraegen C., Kudelka A. P., Kavanagh J. J., Hicks M. E., Lang E. A., Nash M. A., Levy L. B., Garcia M. E., Platsoucas C. D., Abbruzzese J. L., Freedman R. S., Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma Clinical Cancer Research 2002 8 12 3686 3695 (Pubitemid 35428817)
133. Lenzi R., Edwards R., June C., Seiden M. V., Garcia M. E., Rosenblum M., Freedman R. S., Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease 1cm) associated with ovarian cancer or primary peritoneal carcinoma Journal of Translational Medicine 2007 5, article 66
134. Younes A., Pro B., Robertson M. J., Flinn I. W., Romaguera J. E., Hagemeister F., Dang N. H., Fiumara P., Loyer E. M., Cabanillas F. F., McLaughlin P. W., Rodriguez M. A., Samaniego F., Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease Clinical Cancer Research 2004 10 16 5432 5438 (Pubitemid 39100480)
135. Gollob J. A., Veenstra K. G., Parker R. A., Mier J. W., McDermott D. F., Clancy D., Tutin L., Koon H., Atkins M. B., Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma Journal of Clinical Oncology 2003 21 13 2564 2573 (Pubitemid 46606339)
136. Eisenbeis C. F., Lesinski G. B., Anghelina M., Parihar R., Valentino D., Liu J., Nadella P., Sundaram P., Young D. C., Sznol M., Walker M. J., Carson W. E., Phase I study of the sequential combination of interleukin-12 and iterferon afa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12 Journal of Clinical Oncology 2005 23 34 8835 8844 (Pubitemid 46211530)
137. Weiss G. R., O'Donnell M. A., Loughlin K., Zonno K., Laliberte R. J., Sherman M. L., Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder Journal of Immunotherapy 2003 26 4 343 348 (Pubitemid 36858718)
138. Nadler R., Luo Y., Zhao W., Ritchey J. K., Austin J. C., Cohen M. B., O'Donnell M. A., Ratliff T. L., Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity Clinical and Experimental Immunology 2003 131 2 206 216 (Pubitemid 36205130)
139. Luo Y., Han R., Evanoff D. P., Chen X., Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells Clinical and Experimental Immunology 2010 160 3 359 368
140. Fiorentino D. F., Bond M. W., Mosmann T. R., Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones Journal of Experimental Medicine 1989 170 6 2081 2095
141. Fiorentino D. F., Zlotnik A., Vieira P., Mosmann T. R., Howard M., Moore K. W., O'Garra A., IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells Journal of Immunology 1991 146 10 3444 3451
142. Ferguson T. A., Dube P., Griffith T. S., Regulation of contact hypersensitivity by interleukin 10 Journal of Experimental Medicine 1994 179 5 1597 1604 (Pubitemid 24129576)
143. Halak B. K., Maguire H. C., Lattime E. C., Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site Cancer Research 1999 59 4 911 917 (Pubitemid 29086748)
144. Lattime E. C., Mastrangelo M. J., Bagasra O., Li W., Berd D., Expression of cytokine mRNA in human melanoma tissues Cancer Immunology Immunotherapy 1995 41 3 151 156
145. Kruger-Krasagakes S., Krasagakis K., Garbe C., Schmitt E., Huls C., Blankenstein T., Diamantstein T., Expression of interleukin 10 in human melanoma British Journal of Cancer 1994 70 6 1182 1185 (Pubitemid 24358959)
146. Huang M., Wang J., Lee P., Sharma S., Mao J. T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S. M., Human non-small cell lung cancer cells express a type 2 cytokine pattern Cancer Research 1995 55 17 3847 3853
147. Nakagomi H., Pisa P., Pisa E. K., Yamamoto Y., Halapi E., Backlin K., Juhlin C., Kiessling R., Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma International Journal of Cancer 1995 63 3 366 371
148. Mosmann T. R., Schumacher J. H., Fiorentino D. F., Leverah J., Moore K. W., Bond M. W., Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay Journal of Immunology 1990 145 9 2938 2945 (Pubitemid 20382564)
149. O'Garra A., Stapleton G., Dhar V., Pearce M., Schumacher J., Rugo H., Barbis D., Stall A., Cupp J., Moore K., Vieira P., Mosmann T., Whitmore A., Arnold L., Haughton G., Howard M., Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10 International Immunology 1990 2 9 821 832 (Pubitemid 20307067)
150. De Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., De Vries J. E., Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes Journal of Experimental Medicine 1991 174 5 1209 1220
151. Qin Z., Noffz G., Mohaupt M., Blankenstein T., Interleukin-10 prevents dendritic cell accumulation and vaccination with Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Tumor Cells Journal of Immunology 1997 159 2 770 776 (Pubitemid 127484228)
152. Richter G., Kruger-Krasagakes S., Hein G., Huls C., Schmitt E., Diamantstein T., Blankenstein T., Interleukin 10 transfected into chinese hamster ovary cells prevents tumor growth and macrophage infiltration Cancer Research 1993 53 18 4134 4137 (Pubitemid 24146753)
153. Steinbrink K., Wlfl M., Jonuleit H., Knop J., Enk A. H., Induction of tolerance by IL-10-treated dendritic cells Journal of Immunology 1997 159 10 4772 4780 (Pubitemid 127471012)
154. De Waal Malefyt R., Haanen J., Spits H., Roncarolo M. G., Te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., De Vries J. E., Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression Journal of Experimental Medicine 1991 174 4 915 924
155. Ding L., Linsley P. S., Huang L. Y., Germain R. N., Shevach E. M., IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression Journal of Immunology 1993 151 3 1224 1234 (Pubitemid 23219258)
156. Willems F., Marchant A., Delville J. P., Gerard C., Delvaux A., Velu T., De Boer M., Goldman M., Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes European Journal of Immunology 1994 24 4 1007 1009 (Pubitemid 24093803)
157. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., De Vries J. E., Roncarolo M. G., A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Nature 1997 389 6652 737 742 (Pubitemid 27458961)
158. Cenci E., Romani L., Mencacci A., Spaccapelo R., Schiaffella E., Puccetti P., Bistoni F., Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans European Journal of Immunology 1993 23 5 1034 1038 (Pubitemid 23120162)
159. Moore K. W., De Waal Malefyt R., Coffman R. L., O'Garra A., Interleukin-10 and the interleukin-10 receptor Annual Review of Immunology 2001 19 683 765 (Pubitemid 32368050)
160. Bockholt N. A., Knudson M. J., Henning J. R., Maymi J. L., Weady P., Smith G. J., Eisenbraun M. D., Fraser J. D., ODonnell M. A., Luo Y., Anti-IL-10R1 monoclonal antibody enhances BCG-induced TH1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer The Journal of Urology 2012 187 2228 2235